Armata Pharmaceuticalsは、そのバクテリアファージプログラムであるAP-SA02とAP-PA02のために2つの新しい米国特許を取得し、保護期間を少なくとも2041年まで延長しました。
なぜ重要か. Armataの強化された知的財産ポートフォリオは、バクテリオファージ療法分野での競争優位性を高め、リーダー候補製品の保護を強化し、競争相手の参入を遅らせる可能性があります。
using its proprietary bacteriophage-based technology
the company's global IP portfolio consists of 101 issued patents (15 U.S. and 86 ex-U.S.) and 60 pending patent applications (9 U.S. and 51 ex-U.S.) with nominal expiration dates through 2046.
Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041
These newly issued U.S. patents support Armata's leadership in bacteriophage therapeutics and specifically, strengthen the intellectual property ("IP") around the AP-SA02 and AP-PA02 programs, which are highly impactful and potential first- and best-in-class therapies. With pate…
Issued on October 6, 2026, protects methods of treating Staphylococcus aureus infections using its lead product candidate, AP-SA02, which is currently in development for adjunct treatment of complicated Staphylococcus aureus bacteremia ("SAB") caused by methicillin-sensitive S.…
